Form 4: Director Richard Maroun Receives Whitehawk Stock Options

Director Richard E. Maroun was granted 38,040 stock options in Whitehawk Therapeutics, Inc. as part of an equity incentive plan.

Summary

• Director Richard E. Maroun received a grant of 38,040 stock options on June 12, 2026.
• The options have an exercise price of $4.16 per share.
• The options are set to expire on June 12, 2036.
• Vesting occurs on the earlier of the one-year anniversary of the grant or the day before the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the director.

Future Outlook

The options vest in one year or upon the next annual meeting, signaling a commitment to the company's governance and performance over the coming 12 months.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership remains incentivized during long-term drug development cycles.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for small-cap biotech firms.
• The use of a 10-year expiration period is standard for executive and director stock option plans.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 12, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Form 4, Insider Trading, Stock Options, Director Compensation